Mark T. Kershaw

发表

Advancing Parallel Solution Phase Library Synthesis through Efficient Purification, Quantitation, and Characterization Techniques

Susan Virdee, Richard Lew, Jeffrey W. Noonan, 2003 .

Synthesis of 2-aryl-oxazolo[4,5-c]quinoline-4(5H)-ones and 2-aryl-thiazolo[4,5-c]quinoline-4(5H)-ones.

Mark T. Kershaw, K. Hodgetts, 2003, Organic letters.

Aminopyrazine CB1 receptor inverse agonists.

Mark T. Kershaw, J. Krause, J. Mao, 2008, Bioorganic & medicinal chemistry letters.

Ethyl 2-chlorooxazole-4-carboxylate: a versatile intermediate for the synthesis of substituted oxazoles.

Mark T. Kershaw, K. Hodgetts, 2002, Organic letters.

Discovery and optimization of novel piperazines as potent inhibitors of fatty acid synthase (FASN).

David S. Millan, Mark T. Kershaw, K. Bair, 2019, Bioorganic & medicinal chemistry letters.

Aminoquinazolines as TRPV1 antagonists: modulation of drug-like properties through the exploration of 2-position substitution.

Mark T. Kershaw, J. Chandrasekhar, J. Krause, 2008, Bioorganic & medicinal chemistry letters.

Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.

Mark T. Kershaw, S. Boyce, J. Krause, 2010, Journal of medicinal chemistry.

Discovery and Optimization of Quinolinone Derivatives as Potent, Selective and Orally Bioavailable mutant Isocitrate Dehydrogenase 1 (mIDH1) Inhibitors.

Mark T. Kershaw, S. Ashwell, K. Bair, 2019, Journal of medicinal chemistry.

Structure-based design and identification of FT-2102 (olutasidenib), a potent mutant-selective IDH1 inhibitor.

Mark T. Kershaw, S. Ashwell, D. Walker, 2020, Journal of medicinal chemistry.

Regiocontrolled synthesis of substituted thiazoles.

Mark T. Kershaw, K. Hodgetts, 2002, Organic letters.

The design, synthesis and structure-activity relationships of 1-aryl-4-aminoalkylisoquinolines: a novel series of CRF-1 receptor antagonists.

Mark T. Kershaw, J. Kehne, J. Chandrasekhar, 2008, Bioorganic & medicinal chemistry letters.